Overview

A Study to Evaluate the Safety and Effect of STC314 Injection Continuous Infusion in Subjects With Acute Respiratory Distress Syndrome

Status:
Not yet recruiting

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

Summary

This study is a Randomized, Double-blinded, Placebo-controlled Phase Ib Study to Evaluate the Safety, Tolerability and Pharmacokinetics of STC314 Injection Administered as Continuous Intravenous Infusion in Chinese Patients with ARDS (Acute Respiratory Distress Syndrome).

Phase:

Phase 1

Details

Lead Sponsor:

Grand Medical Pty Ltd.

Collaborator:

Grand Pharmaceutical (China) Co., Ltd.